Free erythrbcyte porphyrin (FEP) l e v e l s and red c e l l indices (Coalter Counter Model S) were determined i n 70 normal subjects, 52 with i r o n deficiency and 29 with thalassemia t r a i t i n order t o determine i f these procedures were s u i t a b l e a s screening techniques f o r the detection and i n i t i a l diagn o s i s of i r o n deficiency and thalassemia minor i n subjects with microcytosis. FEP l e v e l s were increased i n 90.2% of s u b j e c t s with i r o n deficiency (mean 167 mcgI100 ml RBC's; range 18-7001, while i n 96.6% of subjects with thalassemia t r a i t , FEP l e v e l s were normal ( l e s s than 70 mcg/100 m l RBC's) . Mean FEP values increased s l i g h t l y a s transf e r r i n s a t u r a t i o n s decreased but became abnormally elevated when t h e t r a n s f e r r i n s a t u r a t i o n was l e s s than 15%. Although subj e c t s with i r o n deficienc exhibited mean corpuscular volumes i n t h e range 46-84 ug, subjects with beta thalassemia t r a i t had values of 70 u3 o r l e s s (mean 62 u3; range 53-70).
A l l non-thalassemic subjects with mean corpuscular volumes l e s s than 70 u3 had t r a n s f e r r i n s a t u r a t i o n s of l e s s than 15%. I n p a t i e n t s with microcytosis, t h e combined use of the e l e c t r o n i c determination of mean corpuscular volume and rapid assay of FEP should be s u i t a b l e f o r i n i t i a l separation of p a t i e n t s with i r o n deficiency from those with thalassemia minor.
VINCRISTINE (VCR) THERAPY AND INAPPROPRIATE ANTIDIURETIC HOR-MONE SECRETION. Marie J . Stuart, Myron Miller and James A.
Stockman, I11 ( I n t r . by Frank A. Oski). Depts. of P e d i a t r i c s and Medicine, Upstate Medical Center and the Veterans Administ r a t i o n Hospital, Syracuse, New York.
Isolated examples of inappropriate ADH s e c r e t i o n following VCR therapy have been described. Stimulated by t h e observat i o n of 3 separate episodes of inappropriate ADH secretion i n a p a t i e n t receiving VCR f o r acute lymphatic leukemia (ALL), an a d d i t i o n a l 6 p a t i e n t s with ALL were studied sequentially during i n i t i a l remission induction. P a t i e n t s received VCR (2 m g l~2 ) weekly x 3 doses and prednisone (40 m g /~2 ) d a i l y f o r a period of 28 days while d a i l y 24-hour u r i n e s were collected f o r ADH immunoassays. I n 6 of 7 patients, s i g n i f icant increases i n ADH s e c r e t i o n occurred during therapy. The g r e a t e s t r i s e was u s u a l l y seen i n t h e 7 t h and 8 t h days following VCR, averaging 18.1 and 14.6 u n i t s /~~/ d a~ (normal baseline 3 . 1 /~2 / d a~) , although i n 3 of t h e 7 p a t i e n t s some increase i n ADH s e c r e t i o n was a l s o noted on day 3 and 4 post-VCR. I n t h e index patient, ADR s e c r e t i o n reached a value of 283 units/M2/day and was associated with profound hyponatremia and seizures. The remainder of t h e p a t i e n t s remained asymptomatic and isosmotic.
Increased A D H s e c r e t i o n appears t o be a comon occurrence following VCR administ r a t i o n . Results demonstrate t h a t LP was s i g n i f i c a n t l y reduced post ASA ingkstion, and gradually returned t o normal i n 10 days. Concomitant p l a t e l e t aggregation s t u d i e s returned t o normal a f t e r 4 days with epinephrine and by day 8 with thrombin. The i n h i b i t o r y e f f e c t of ASA on p l a t e l e t LP p a r a l l e l s its e f f e c t on aggregation but is a more s e n s i t i v e index of the "aspirin defect" a s i t remains present f o r the e n t i r e l i f espan of t h e p l a t e l e t . These findings suggest an i n t e r a c t i o n between ASA and p l a t e l e t membrane sulhydryl groups i n t h e mechanism of aggregation.
Sylvia
A sample, from a 2 year period , of h o s p i t a l records f o r 57 p a t i e n t s with s i c k l e c e l l anemia were examined t o determine t h e c o s t of h o s p i t a l i z a t i o n and treatment t o a s s e s s medical expenses and t o obtain a t e n t a t i v e p r o f i l e of age, length of s t a y , and type of services u t i l i z e d . The average age of p a t i e n t s was 16.7 years (R:5 mos.-39 y r s . ) . Length of s t a y averaged 13.8 days (R:l-196 days). Breakdown of data per h o s p i t a l i z a t i o n i s presented a s averages: age (N=57) 16.7 y r s . , days i n h o s p i t a l (N=57) 13.77, room and board (N=57 (N=57) $876.40. I n terms of age categories, the 0-11 year old group average h o s p i t a l costs were nearly half t h e c o s t of the 20-39 year old group. Approximately 50% of the payments were made by health insurance companies, 31% by Medicaid, and 17% by p r i v a t e means.
This information can be u t i l i z e d i n the comprehensive planning and management of p a t i e n t s with s i c k l e c e l l anemia. Growth Hormone (GH) has been shown t o stimulate erythropoiesis and increase red c e l l volume (RCV) i n children and animals who had e i t h e r isolated G H deficiency or s u r g i c a l hypophysectomy. I n an attempt t o confirm t h a t t h i s e f f e c t i s a l s o related t o the growth response of t h i s hormone we studied 7 GH d e f i c i e n t children. 6 of the children had r educed RCV (mean 15.5 ? .8 mllkg). The 7th (AK) had a normal RCV of 22 ml/kg (N 22-27 ml/kg). The mean erythropoietin level in the 6 children who had reduced RCV was .6 + . 1 % R B C~~F~ Inc. After 6 weeks of GH the RCV was 23.7 + 1.2 ml/kg. The erythropoietin increased t o a value of 3.2 + .6 % R B C~~F~ a f t e r 1 week of therapy in the 6 children with r educed RCV and decreased t o 2 . 0 ? .4 % R B C~~F~ a f t e r 6 weeks of GH therapy. The growth of these 6 p a t i e n t s was 3.5
.25 inches for the 1 s t year. A K did not increase her erythropoietin during therapy. Her growth was 1.25 inches during her 1 s t year of GH. Her GH assays were repeated and i t was again decreased ( l e s s than 1 nanogram/ml by i n s u l i n t o l e rance t e s t ) .
W e believe t h a t the erythropoiesis t h a t occurs a f t e r GH administration in a GH d e f i c i e n t child with a reduced RCV i s related t o erythropoietin secretion and t h i s response maybe related t o the hormones'growth e f f e c t .
SECOND PRIMARY TUMORS I N CHILDREN WITH CANCER AND LEUKEMIA. Jaw J. Wan Children who have cancer o r leukemia usually have an abbreviated l i f e span i n which another tumor could manifest i t s e l f as compared t o an a d u l t population. This study includes a survey o f children w i t h leukemia o r cancer below 16 years o f age seen from June 1946 t o December 1971 a t RPMI. Sixteen o f 884 cases (1 -8%) showed the presence o f a second primary tumor (SPTJ. There were 12 malignant and 4 benign lesions. Among 371 cases o f acute leukemia, only 1 SPT was found. Three cases o f SPT, including one each o f Hodgkin's Disease, fibrosarcoma and osteosarcoma were observed i n retinoblastoma patients. Among 41 cases o f Wilm's Tumor, 2 SPT, including one chondrosarcoma and one osteochondroma were found. One p a t i e n t w i t h Hodgkin's Disease and chronic myelocytic leukemia had Positive Philadelphia Chromosome. One p a t i e n t w i t h xerodermia developed both squamous c e l l carcinoma and ma1 ignant me1 anoma. Two children w i t h glioblastoma multiforme and rhabdomyosarcoma developed hepatoblastoma. A neuro-astrocytoma was observed i n one c h i l d w i t h acute leukemia and i n one w i t h adenocarcinoma o f the colon. One child, who was cured o f glioblastoma multiforme, developed reticulum c e l l sarcoma. I n 7 children the SPT were detected a t the time o f diagnosis o f the primary malignancy. I n 4 cases the SPT occurred 2.5-16 years a f t e r radiotherapy and were poss i b l y r a d i a t i o n induced.
